Friday, October 9, 2015

Adheron Therapeutics Acquired By Roche For $105M

Berkeley-based Adheron Therapeutics has been acquired by Roche, in a deal worth $105M in an upfront payment, plus earnout worth up to an additional $475M. Adheron Therapeutics develops technology that disrupts immune cell adhesion, which is being applied to treatments for inflammatory and autoimmune diseases, including rheumatoid arthritis. Adheron Threapeutics is led by Hari Kumar, and was venture backed by Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, Amgen Ventures, and SROne.